We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rectal Colonization by Klebsiella Leads to Different Risks for Bacteremia

By LabMedica International staff writers
Posted on 20 Jul 2021
Carbapenem-resistant Enterobacterales (CRE) represent a threat for public health, being among the top multidrug-resistant pathogens. More...
Intestinal colonization by CRE is a risk factor for developing subsequent infection.

In patients colonized by Klebsiella pneumoniae Carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp), the rate of bloodstream infections (BSI) ranges from 8% to 23%, and specific factors for development of subsequent BSI have been identified. K.pneumoniae typically colonizes human mucosal surfaces of the oropharynx and gastrointestinal (GI) tract.

Infectious Disease specialists at the Pisan University Hospital (Pisa, Italy) and their colleagues carried out single-center, longitudinal, prospective, observational study involving consecutive adult patients with rectal colonization by CR-Kp admitted to the hospital from December 2018 to December 2019. After initial screening, all hospitalized patients were monitored through periodical rectal swabs on a regular basis (once a week in non-ICU and twice a week in ICU wards).

Rectal swabs were processed using three sequential steps: 1) molecular detection of bla genes involved in carbapenems resistance, 2) culture and pathogen identification, and 3) antibiotic susceptibility testing. Molecular screening was performed by the GeneXpert System Xpert-CARBA test (Cepheid, Sunnyvale, CA, USA). Species identification was performed using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility tests were performed with the SensiTitre system (Thermo Fisher Scientific, Waltham, MA, USA). Isolates were subjected to whole-genome sequencing (WGS) with an Illumina MiSeq platform (Illumina, San Diego, CA, USA). Rectal carriers were classified as: NDM, KPC, VIM and OXA-48.

The scientists reported that of 677 rectal carriers, 382/677 (56.4%) were colonized by NDM, 247/677 (36.5%) by KPC, 39/677 (5.8%) by VIM and 9/677 (1.3%) by OXA-48. Dissemination of NDM-KP was mostly sustained by ST147, while KPC-kp belonged to ST512. A higher rate of BSI was documented in NDM-compared to KPC-rectal carriers: 59/382, (15.4%) versus 20/247, (8.1%). Incidence rates of BSI/100 patients/month were significantly higher in the NDM (22.33) than in the KPC group (9.56). On multivariate analysis, multi-site extra-intestinal colonization, solid organ transplantation, invasive procedures, intravascular device, ICU, cephalosporin, fluoroquinolones and NDM rectal colonization (odds ratio [OR] = 3.27) were independently associated with BSI.

The authors concluded that their patients colonized by NDM-Kp are at higher risk of bacteremia compared to those colonized by KPC-Kp and the carbapenemase type is strongly related to the specific ST. Thus, the findings may reflect an increased virulence of the ST147 clone of Kp. The study was published on June 27, 2021 in the journal Clinical Microbiology and Infection.

Related Links:
Pisan University Hospital
Cepheid
Bruker Daltonics
Thermo Fisher Scientific
Illumina



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.